期刊文献+

放射性125I粒子植入治疗非小细胞肺癌近期疗效的多因素分析 被引量:18

The short term therapeutic effects of radioactive 125I seeds implantation for treatment of non.small-cell lung cancer
原文传递
导出
摘要 目的探讨影响放射性125I粒子植入治疗非小细胞肺癌(NSCLC)近期疗效的因素。方法141例原发性NSCLC患者实施CT引导下放射性125I粒子植入治疗,其中26例单纯粒子植入,115例粒子植入联合化疗。所有患者术后6个月行胸部CT检查,根据肿瘤大小变化进行疗效评估,并分析影响近期疗效的相关因素。结果(1)粒子植入后完全缓解37例,部分缓解93例,有效率92.2%。(2)单因素分析显示:肿瘤分型(F=5.162,P=0.023)、覆盖100%肿瘤瘤体剂量(D100)(F=100.713,P=0.000)、治疗模式(F=16.205,P=0.000)对局部疗效有影响。单因素logistic回归分析显示:D100、治疗模式、肿瘤分型均为影响局部疗效的独立因素。(3)单因素分析显示:肿瘤分型(X2=7.313,P=0.007)、D100(X2=71.6,P=0.000)、治疗模式(X2=20.5,P=0.000)均为影响晚期NSCLC粒子植入治疗效果的重要因素。所有患者治疗期间均未发生相关严重并发症,且与近期疗效无明显相关(P〉0.05)。结论CT引导下放射性125I粒子植入治疗NSCLC是一种安全、有效的治疗方法D100为影响近期疗效最主要因素。 Objective To explore influential factors of local therapeutic effect in CT guided braehytherapy of 125I seeds for non-small-cell lung carcinoma (NSCLC). Methods Totally 141 primary NSCLC patients diagnosed by bronchoscope or puncture biopsy were treated with CT guided 125I seeds implantation treatment from 2003 January to 2005 January. Among them, 26 patients were treated with seeds implantation only and remaining 115 combined with chemical therapy. Preplaus were performed by using treatment planning system before the implantation. We took the implantation with the prescription dose of 80- 110 Gy, 1 seed per 1 cm3, under the guide of computed tomography. Six months after implantation treatment, CT graphs were taken to evaluate the therapeutic effect. Results All the patients were survival until 6 months after implantation, and 37 were complete remission, 93 were partial remissions. The effective rate was 92. 2%. Among all the observed factors, pathologic type ( F = 5. 162, P = 0. 023 ), dose of cover 100% tumor ( D100 ) ( F = 100. 713, P = 0. 000 ) and treatment methods ( F = 16. 205, P = 0. 000 ) were the independent influent factors ( P 〈 0. 05 ). Among these, D100 was the most important factor ( P = 0. 000 ). Single factor analysis indicated that pathologic type (X2 =7. 313, P =0. 007), Dr00 (X2 =71.6, P =0. 000) and treatment methods 0(2 = 20. 5, P = 0. 000) were significant influent factors. Of all 141 cases, 24 had complications during or after implantation treatment ,while no severe complications were reported. There was no significant correlation between complication and local therapeutic effect ( P 〉 0.05 ). Conclusion CT guided implantation of 125I seeds for lung cancer has good clinical effects and few complications. D100 is the most important factor to influence the local therapeutic effect. Implantation treatment combined with chemotherapy is an ideal measure for NSCLC treatment.
出处 《中华内科杂志》 CAS CSCD 北大核心 2012年第12期978-981,共4页 Chinese Journal of Internal Medicine
关键词 非小细胞肺 粒子 治疗结果 因素分析 统计学 Carcinoma, non-small-cell lung Particles Treatment outcome Factor analysis, statistical
  • 相关文献

参考文献13

  • 1Older RA, Synder B, Krupski TL, et al. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy.J Urol ,2001,165: 1590-1592.
  • 2Martinez-Monge R, Nag S, Martin EW. 125Iodine brachytherapy for colorectal adenocarcinoma recurrent in the pelvis and paraortics. IntJ Radiat Oncol Bioi Phys, 1998 ,42 :545-550.
  • 3Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of 1-125 brachytherapy seeds. Ann Thorac Surg,2003,75:237-243.
  • 4Gaspar LE, Zamorano W, Shamsa F, et al. Permanent 125 iodine implants for recurrent malignant gliomas. IntJ Radiat Oncol Bioi Phys,1999,43:977-982.
  • 5Vikram B. "Permanent iodine-125 (I-125) boost after teletherapy in primary cancers of the nasopharynx is safe and highly effective: long-term results". IntJ Radiat Oncol BioI Phys, 1997 ,38 : 1140.
  • 6Martinez-Monge R, Pagola M, Vivas I, et al. CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). Lung Cancer, 2008,61 :209-213.
  • 7柴树德,郑广钧,毛玉权,杨景魁,梁吉祥,闫卫亮.CT引导下经皮穿刺种植放射性^(125)I粒子治疗晚期肺癌[J].中华放射肿瘤学杂志,2004,13(4):291-293. 被引量:92
  • 8郑伟,聂青,康静波,温居一.老年Ⅲ期非小细胞肺癌同步放化疗的临床对照研究[J].中华肿瘤防治杂志,2012,19(4):292-296. 被引量:19
  • 9Choy H. Chemoradiation in NSCLC : focus on the role of gemcitabine. Oncology (Williston Park) ,2004,18 (8 Suppl 5) : 3842.
  • 10Zhang S, Zheng Y, Yu P, et al. The combined treatment of CT-guided percutaneous 1251 seed implantation and chemotherapy for non-small-cell lung cancer.J Cancer Res Clin Oncol,2011, 137: 1813-1822.

二级参考文献29

  • 1胡效坤,王明友,杨志国,邱春东,吕东方,李晓东,左太阳.CT导引下经皮穿刺组织间植入^(125)I放射微粒子治疗中心型肺癌的应用研究[J].中华放射学杂志,2004,38(9):910-915. 被引量:117
  • 2黄振国,张雪哲,王武,洛小林,王继英.CT导引下^(125)I粒子植入在治疗恶性肿瘤中的应用[J].中华放射学杂志,2004,38(9):921-925. 被引量:135
  • 3金普乐,张钧,梁健.^(125)I粒子不同放射剂量治疗癌性气道狭窄[J].肿瘤,2006,26(6):570-572. 被引量:3
  • 4秦明秀 刁国平 等.临床介入核医学[M].天津:天津科学技术出版社,1996.209-241.
  • 5谷铣之.肿瘤放射治疗学[M].-,1991.504-505,517-518.
  • 6Marchese MJ, Hall EJ, Hilaris BS, et al. Encapsulated iodine-125 in radiation oncology. Am J Clin Oncol, 1984, 7:607-611.
  • 7Goffinet D, Ling CC, Mariscal M, et al. Using of 125I in breast implants. Endocur Hypertherm Oncol, 1987, 3:121-125.
  • 8De Silva VF, Gutin PH, Deen DF, et al. Relative biological effectiveness of 125I sources in a murine brachytherapy model. Int J Radia Oncol Biol Phys, 1984, 10:2109-2111.
  • 9华积德,主编.肿瘤外科学.北京:人民军医出版社,1995.1703.
  • 10Hilaris BS, Nori D, Beattie EJ, et al. Value of perioperative brachytherapy in themanagement of non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys, 1983,9:1161-1166.

共引文献168

同被引文献151

引证文献18

二级引证文献159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部